Royalty Pharma Sub-Manager, LLC
An institutional investment manager in New York, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 21, 2026. SEC CIK 2081668.
- Reported value$241.9m
- Positions4
Holdings: 4 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Cytokinetics, IncCYTK | COM | 23282W605 | 83.5 | 34.5% | 980,392 | Unchanged | |
| Zenas Biopharma, Inc.ZBIO | COM | 98937L105 | 60.6 | 25.1% | 2,388,150 | New+2,388,150 | |
| Kailera TherapeuticsKLRA | COM | 482931102 | 54.1 | 22.4% | 2,455,357 | New+2,455,357 | |
| Biohaven Ltd | COM | G1110E107 | 43.7 | 18.1% | 2,936,507 | Unchanged |
Sold out: 2 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals IncBCRX | COM | 09058V103 | 0.0 | 0.0% | 0 | Sold out−3,846,154 | |
| Zenas Biopharma, Inc.BCAX | COM | 055477103 | 0.0 | 0.0% | 0 | Sold out−2,388,150 |
Source: SEC EDGAR, Form 13F-HR, accession 0002081668-26-000018 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.